✦ LIBER ✦

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

✍ Scribed by Wheler, Jennifer J.; Janku, Filip; Falchook, Gerald S.; Jackson, Tiffiny L.; Fu, Siqing; Naing, Aung; Tsimberidou, Apostalia M.; Moulder, Stacy L.; Hong, David S.; Yang, Hui; Piha-Paul, Sarina A.; Atkins, Johnique T.; Garcia-Manero, Guillermo; Kurzrock, Razelle

Book ID: 121544946
Publisher: Springer
Year: 2014
Tongue: English
Weight: 386 KB
Volume: 73
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-014-2384-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I safety, pharmacokinetic and phar

Phase I safety, pharmacokinetic and pharmacodynamic study of recombinant human anti-VEGF antibody HuMV833 in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Phase 1 study of the histone deacetylase

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

✍ Garcia-Manero, G.; Yang, H.; Bueso-Ramos, C.; Ferrajoli, A.; Cortes, J.; Wierda, 📂 Article 📅 2008 🏛 American Society of Hematology 🌐 English ⚖ 795 KB

Phase I study of chidamide (CS055/HBI-80

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

✍ Dong, Mei; Ning, Zhi-Qiang; Xing, Pu-Yuan; Xu, Jia-Lian; Cao, Hai-Xiang; Dou, Gu 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 472 KB

Phase I clinical, pharmacokinetic and ph

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

✍ Razak, A R A; Hotte, S J; Siu, L L; Chen, E X; Hirte, H W; Powers, J; Walsh, W; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 308 KB

394 A phase I dose escalation and pharma

394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours

✍ F. Eskens; L. van Doorn; D. Papadatos-Pastos; P. Debnam; M. Tall; M. Toal; L. Ho 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A Phase II and Biomarker Study of Ramuci

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

✍ Zhu, A. X.; Finn, R. S.; Mulcahy, M.; Gurtler, J.; Sun, W.; Schwartz, J. D.; Dal 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 517 KB